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Abstract
Integrins are heterodimeric molecules that are composed of 18 α-subunits and 8 β-subunits. They exist in 24
distinctive shapes based on combination of these sub-units and are mainly responsible for the adhesion of
extracellular matrix (ECM) and immunoglobulin family molecules. Integrins mediate adhesion of epithelial cells to the
basement membrane and also help in the migration, proliferation and survival of tumor cells. Studies also reveal that
certain integrins act as markers for tumor cells and they also assist in both tumor progression and apoptosis. Studies
reveal that unligated integrins in association with caspase 8 result in inhibition of ECM adhesion might result and
integrin mediated death (IMD) on the other hand integrins in association with oncogenes or receptor tyrosine kinases
can result in enhanced tumorigenesis. Among several types of integrins, αvβ3 and α5β1 have gained importance in
anti-angiogenesis studies.
Hence the role of antiangiogenesis antagonists has come into light. These include a variety of monoclonal
antibodies and peptides. Each one of them has their own mechanism of action and antiangiogenesis activity.
Current review aims at studying the phase 1 and 2 trails of these antagonists for anti-angiogenic function.




Integrins are a heterodimeric cell surface receptors that assist in the
adhesion of extracellular matrix (ECM) and immunoglobulin family
molecules. They play a vital role in the cell motility and invasion as
they can directly adhere to the various components of the ECM.
Integrins also control the ECM remodeling and proliferation processes
[1]. Integrins are a family of heterodimeric molecules that are
composed of 18 α-subunits and 8 β-subunits. They exist in 24
distinctive structures by the combination of these subunits, each one
with multiple activation sites and distinctive expression and
glycosylation activity based on their composition. The extent to which
a cell can adhere or migrate on different matrices can be determined
by the composition of the integrin it possesses. The presence of RGD
(Arg-Gly-Asp) sequence in the respective ligands can be identified by
the presence of the αv and α5β1 integrins [2]. Furthermore the
presence of various adhesive sequences in the ECM proteins such as
EILDV (Glu-Ile-Leu-Asp-Val) and REDV (Arg-Glu-AspVal) can be
identified by the presence of the α4β1 integrin. On ligating to the
ECM, integrins cluster and recruit various signaling and adaptor
proteins at a particular site called as focal adhesion point to initiate
important cellular functions. The composition of such sites are truly
depend on the 2 or 3 dimensional contact conditions. At the enriched
site, integrins inherit kinase functionality by recruiting active kinases
such as Focal adhesion kinases (FAK’s) and SRC family kinases
(SFK’s), assist in the association of ECM to actin- cytoskeleton by
recruiting proteins such as talin, paxilin, α-actinin, tensin and vinculin
and further associated with cellular migration and survival the help of
PINCH (a territory complex consisting of an integrin linked kinase)
and Parvin. A group of membrane proteins called Tetraspanins are
responsible for regulating the integrin function in the tumor cells by
recruiting integrins to the membrane microdomains. The extent of cell
adhesion and migration on ECM is controlled by the recruitment
specific integrins and other Focal adhesion proteins, which in turn
became potential candidates for cancer therapy [3-6].
Cell survival is maintained by various integrin mediated
mechanisms involving increase in expression of BCL-2, activation of
PI3K-AKT, p53, vascular endothelial growth factor 2 (VEGFR2)
pathways and by preventing the intrinsic and extrinsic apoptosis
pathways [7]. Unligated integrins together with caspase 8 can induce
integrin –mediated death (IMD), which is different from anoikis.
Under normal conditions integrins assist in regulating the integrity
of the various organs and tissues of the body. The previous studies
reveal that α5β1 integrin, could assist in tumor progression by
activating the oncogene-induced transformation. The solid tumors
formed from epithelial cells are found to be with higher level of α6β4,
α6β1, αvβ5, α2β1 and α3β1 integrins and retained with different
expression levels during tumor cell survival, proliferation, progression
and migration. The higher expression levels of integrins αvβ3, α5β1
and αvβ6 in some tumors acts as the marker proteins, while they are
under expressed in normal epithelial cells [6]. Integrins in association
with oncogenes or receptor tyrosine kinases can result in enhanced
tumorigenesis. Integrin α6β4 along with ERBB2 in breast cancer and
α1 activated KRAS-G12D- induce tumors in the lung [3,4,8,9]. Beyond
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to the advantages and disadvantages of various integrins, the
therapeutic effects of integrin antagonists still remained unexplored as
it is believed that inhibition of ECM adhesion might result in IMD. In
the current review, we have selected the important of two αvβ3 and
α5β1 integrins to enumerate the importance in the generation of
antagonists in the treatment of cancer.
Integrin αvβ3: The αvβ3 integrins are a part of a family of αv
integrins, a group of five members: αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8
whose prime function is regulation of cell adhesion to ECM,
proliferation and migration. It adheres to the extracellular matrix
proteins using an amino acid sequence of arginine-glycine-aspartic
acid [6,10,11]. The αvβ3 integrin, vitronectin receptor is a member in
the family of αv integrins, a group of 5 members: αvβ1, αvβ3, αvβ5, αvβ6
and αvβ8 whose prime function is regulation of cell adhesion to ECM,
proliferation and migration. It adheres to vitronectin, an extracellular
matrix protein with the help of RGD sequence [6,10,11]. These are the
prime type of integrins that are present in the endothelial cells and
helps in angiogenesis via the basic fibroblast growth factor (bFGF) and
tumor necrosis factor-α and also contribute to the malignant spread of
various tumor cells such as breast carcinoma, prostrate carcinoma and
melanoma [12-14]. Up regulation of αvβ3 integrin is observed
profoundly upon neo-vessel formation to vascularize the most of the
human cancer cells during angiogenesis and invasion [6,15,16]. Hence
the inhibition αvβ3 integrin by cyclic RHD peptides, peptidomimetics
and monoclonal antibodies induce endothelial cell apoptosis there by
resulting in angiogenesis inhibition and are considered as potential
targets to attain antiangiogenic properties.
Integrin α5β1: α5β1 integrin interacts with fibronectin (ECM
glycoprotein) at the RGD sequence and plays a crucial role in
neovascularization by generating survival signals for active endothelial
cells and mediates angiogenesis by regulating endothelial cell growth,
proliferation and migration in cancerous cells by suppressing the
protein kinase A (PKA) [3,4,17]. Stimulation of angiogenesis growth
factors such as bFGF, TNFa and IL8 result in the upregulation of
integrin α5β1 and its expression is controlled by the home box family
transcription factor 3 (Hox 3) [18-21]. The inhibition α5β1 integrin via
certain antagonists such as antibodies or small molecules results in the
inhibition of endothelial cell survival and proliferation both in vivo
and in vitro to block angiogenesis and there by resulting in apoptosis.
Integrin antagonists in tumor and angiogenesis inhibition
Integrin antagonists in clinical development include both
antibodies and small molecules (Table 1) These antagonists include:
(a) chimeric or humanized antibody inhibitors. (b) peptide inhibitors
of individual integrins as well as peptides that inhibit integrins, and (c)
non-peptide, organic inhibitors. In the current review, an attempt is
made to target αv and α5 integrin with different integrin-targeted
agents, which are in clinical development and clinical trials in cancer
therapy.
Integrin Antagonists Function Disadvantage/
Advantage
avb3 Monoclonal ab
Vitaxin (LM 609 mAb)
Inhibits cell adhesion, blocks Vitronectin receptors & Bax
apoptotic pathway, upregulates matrix degradation inhibitors
Short half life and inefficient interaction
No tumor regression
First generation of MEDI – 523 &
Second generation of MEDI-522
Inhibits MAPKinase pathway, inhibits MMP- activation, lowers
TGF- β1 accumulation
No clinical significance due to less affinity
and stability
Intetumumab (CNTO 95) Inhibits the contact between ECM and tumor cells, inhibits
angiogenesis
Safe for long term administration
EMD 525797 (DI17E6) mAb
Non-peptide inhibitors
MK0429
Inhibits the ligand binding to αv heterodimers Efficacy, dose dependent tolerability and
under phase II trails
PSK1404 Inhibits osteoclast formation in bone metastasis Oral compound is not developed even
though safe and tolerable
Preclinical study is limitedIH1062 Inhibits osteoclast bone resorption and inhibits ovarian andbreast cancer
S 137 and S247
17E6
Inhibit the cell growth and enhance apoptosis by inhibiting the
interaction with ligand Inhibits vitronectin binding,
Inhibits pulmonary metastasis
Provides promising results in tumor
metastasis
GIPG0187,RGD antagonists Decreases BCl-2/Bax ratio and survivin protein Reduces the development of liver
metastasis




Promotes endocytosis of αvβ3 integrin, Anti tumor, anti
adhesive and anti metastatic activities




Inhibits VEGF expression and angiogenesis
Under clinical trial
Under Phase I trails in cancer therapy
Novel in anti-metastatic therapy
Under Phase II trails
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Inhibits MMP-2 activity
Inhibits angiogenesis and metastasis by reducing VEGF
expression
Anti tumorigenic and anti metastatic
Prevents recurrence of cancer
α5β1 Volociximab Inhibits the function of α5β1integrin
Induces apoptosis in cancer cells Inhibits angiogenesis
Inhibits tumor growth significantly
GIPG0187, non peptide RGD
antagonists




Under Phase I trails in cancer therapy
Resveratol, natural polyphenolic
antioxidant
Down regulates α5β1 integrins
Induces apoptosis
Further study is required
Table 1: Monoclonal antibodies and other non peptide mediated antagonists of αvβ3 and α5β1 integrins and the details are given in the text.
Vitaxin: Vitaxin is a function blocking humanized monoclonal
antibody that specifically interacts with the integrin αvβ5 [22]. The
humanized version is derived from the LM 609 antibody [11,23]. The
LM 609 antibody is the most specific anti-integrin αvβ5mAb which
blocks the interaction of αvβ5 complex with its matrix ligands and
inhibits the cell adhesion [14]. The LM 609 mAb blocks the VN
receptor in the presence of growth factor stimulation and results in
activation of p53. It also leads to increase the BAX apoptosis pathway
by enhancing the p21waf-1/CID-2 levels. This molecular mechanism
triggers the apoptosis of endothelial cells and regression of angiogenic
blood vessels. It also blocks the induction of TGF-β1 and stimulate
SMC migration by inducing the expression of various ECM proteins
and at the same time up regulate the expression of matrix degradation
inhibitors and tissue inhibitors of MMPs [24,25]. Despite of numerous
clinical studies the therapeutic approach of LM 609 is limited in
humans due to its short serum life and inefficient interactions with
human immune effector cells [14].
To overcome these issues LM 609 is humanized to interact
specifically with integrin αvβ5 and Vitaxin is the first generation
(MEDI-523) of humanized version that is developed. The humanized
version comprise the human IgG1, kappa and grafted murine CDRs
onto human framework and their by retaining the parent monoclonal
LM 609 antibody properties [14,26]. Vitaxin binds to conformational
epitope that is formed by αv and β5 subunit with equal affinity [24]. By
preventing Erk ½ phosphorylation, it suppress the tumor growth and
also angiogenesis. Blockade of integrin αvβ5 by vitaxin is able to block
the conversion of pro MMP-2 to active MMP-2 thereby preventing the
localization and activation of MMP-2 [11].
The in vivo studies performed in the ballon injured
hypercholesterolemic rabbit demonstrated that vitaxin dose
dependently inhibited Rb-1 SMC migration at 20 µg/mL
concentration. Vitaxin significantly reduces neointima formation in
both LDV and HDV groups even in presence of hypercholesterolemia,
a stimulus to integrin αvβ5 accumulation. It also reduced the artery
size, enhanced cellular apoptosis in injured arteries and lowered the
amount of TGF-β1 accumulation. These results encouraged to study
the efficacy of with integrin αvβ5blockade [11]. Later the safety and
pharmacokinetics of the vitaxin where evaluated in Phase-I clinical
studies. In this Phase-I, open label, single centre, dose escalating study
patients with late stage breast, lung, colon cancer were administered
intravenously with increasing doses of vitaxin (0.1 mg/kg-4.0 mg/kg)
for six weeks. The drug therapy was well tolerated with no significant
toxicity at any dose level. The pharmacokinetics of the vitaxin
demonstrated a dose dependent elimination because the half-life of the
vitaxin is 4-9 fold lower when compared to higher dose and tend
towards non linearity. Even though this study did not determine the
optimum dose it suggested that vitaxin could administered safely
without any toxicity over prolonged periods and evidenced that
humanized vitaxin does not appear to be immunogenic [22]. The
optimum dose of the vitaxin was characterized in a pilot trail
conducted in patients with metastatic cancer. This clinical trial
suggested that the doses level of vitaxin equivalent to or in excess 50
mg can be administered and to maintain circulating levels with good
plasma recovery a dose of 200 mg is recommended. Because the half-
life plasma recovery for 10 mg dose level was very low, for 50 mg it was
76% and for 200 mg it was 95%. The treatment was well tolerated with
no tumor regression [25]. But due to the absence of significant clinical
responses, affinity and stability in vivo issues of MEDI-523 encouraged
to develop second generation humanized anti integrin αvβ5
monoclonal antibody MEDI-522 (Abegrin).
The second generation MEDI-522 derived from MEDI-523 have
greater affinity and stability towards integrin αvβ5. It also retained the
tumor targeting and antibody retention properties from predecessor
mAb [23,27]. The preclinical in vitro and in vivo inhibitory studies
suggested that the continuous serum concentration at a minimum of
10 µg/mL to 30 µg/mL is sufficient for MEDI-522 activity. The safety
and tolerability of MEDI-522 was evaluated in Phase-I, open label,
dose escalation trail. The patients with solid tumors were treated with
MEDI-522 with dose levels ranging from 2 to10 mg/kg. No significant
toxicity and maximum tolerated dose was identified but few adverse
events noted were low-grade constitutional symptoms, gastro
intestinal symptoms, infusion reactions and asymptomatic
hypophosphatemia. Only three patients with metastatic renal cell
cancer experienced prolonged stable disease on treatment suggesting
that MEDI-522 could be further investigated as an anti-integrin αvβ5
[13].
The clinical studies that used immunotherapy with radionuclides
showed efficacy of the MEDI-522 and the level of radiotherapy and
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molecular inhibition was also established. In the in vitro and in vivo
micro PET studies, MEDI-522 (AbegrinTM) was conjugated with
DOTA and labelled with 64Cu. The 64Cu-DOTA-AbegrinTMconjugate
exhibited high integrin αvβ5 specificity with shorter half-life in mouse
than in humans [28]. In the tumor imaging studies by using 111In-
DOTA-AbegrinTM conjugate the uptake of the conjugate is high in
integrin αvβ5 positive tumors when compared to the αvβ5 negative
tumors and there by exhibiting the high binding affinity to human
integrin αvβ5 [29]. The efficacy and maximum tolerate dose of Abegrin
was evaluated in a murine xenograft glioblastoma model in which
DOTA-Abegrin was conjugated with 90Y. Animals treated with 300
µCi had higher mortality rate and reduction in all hematologic counts.
The distribution of the antibody was found high in liver and spleen
and serum t 1/2 of 90Y-DOTA-Abegrin was found to be 12-24 hours.
The maximum dose tolerated was 200 µCi with maximum antitumor
efficacy and no toxicity was observed with good hepatic clearance [30].
The success of radio labelled imaging in vitro and in vivo studies of
Abegrin using radionuclides provides the success in to clinic to
evaluate the tumor targeting efficacy, dose optimization, dose interval
and pharmacokinetics of MEDI-522.
The Phase-I study of the MEDI-522 evaluated the safety,
immunogenicity and pharmacokinetics in sixteen patients with solid
tumors in dose escalating manner (1, 2, 4 and 6 mg/kg). The treatment
was well tolerated at doses upto 6 mg/kg and no evidence of
immunogenicity was observed. The only biological effects observed
were leucopenia, anaemia, hypocalcemia, hypokalemia, hyponatremia
and hypophosphatemia. The pharmacokinentic analysis observed a
nonlinear increase in half-life [31]. The antitumor efficacy and safety
data of MEDI-522 were assessed in randomized, open-label, two arm
Phase-II study. The stage-IV melanoma patients were randomized to
receive MEDI-522 and MEDI-522 + dacarbazine. The therapy with
MEDI-522 + dacarbazine did not appear to be more effective in
metastatic melanoma and the most adverse events observed were
gastro intestinal, metabolic and infusion related [32]. These studies
specified the binding efficacy of the MEDI-522 for human integrin
αvβ5 Phase I/II clinical studies and will enter Phase III for further
evaluation.
Volociximab: Volociximab, clinically represents as a first function
blocking, high affinity human/mouse chimeric IgG4 monoclonal
antibody that specifically interacts with integrin α5β1 [33]. The
constant region of volociximab comprises human IgG4 heavy and
kappa light chain combined with murine antibody variable regions,
including the integrin α5β1 directed complementarity determining
regions [34,35].
In vitro models of angiogenesis, a preclinical evaluation study of
volociximab suggest that volociximab is potent inhibitor of
angiogenesis. It inhibits the α5β1 integrin function by inducing
apoptosis in proliferating endothelial cells but not resting cells. The in
vivo studies conducted in cynomolgus model of revascularization also
suggest that voloxicimab inhibit integrin α5β1 function with a greater
inhibitory potential. These data demonstrated that volociximab has
therapeutic potential in diseases such as cancer and age- related
macular degeneration [36]. The antitumor activity assessment of
volociximab in syngeneic rabbit VX2 carcinoma model reported that
systemic administration of volociximab whether prophylactically or
after the tumor establishment as a potent anti-cancer agent. These
studies supported the use of volociximab as potent inhibitor in
malignant disease because when maintained relatively high levels of
antibody for at least two weeks in the model there was significant
decrease in tumor volume growing subcutaneously or intramuscularly
[37].
The safety profile, feasibility, anticancer activity, pharmacokinetic
and pharmacodynamic behavior of volociximab were evaluated in the
phase I study based on the supporting rationale provided by the
preclinical studies. In this multicentre, open label, dose-escalation
study of 21 patients with tumors, showed unresponsive to standard
therapies were administered with volociximab. Over 60 min at dose
levels ranging from 0.5 to 15 mg/kg with a total of 223 infusions. But,
observed no DLT and neither required dose reductions. The common
adverse events observed in high dose groups were fatigue and
myalgias, however, there was neither hematologic toxicity nor
infectious complications. But few non-hematologic adverse events
which included gastrointestinal symptoms, head ache, edema,
hypertension and low grade constitutional symptoms were observed.
The binding and saturation of integrin α5β1 sites by volociximab was
determined as a dose-dependent because estimates of volociximab
declined with increasing doses which was achieved at the highest dose
of 15 mg/kg. These findings suggested that volociximab can be safely
administered to target multistep angiogenesis process in a feasible and
safe approach [38].
The non-randomized Phase II disease specific clinical trials for
volociximab were carried in patients with malignant melanoma,
pancreatic, renal cell carcinoma, ovarian and non-small cell lung
cancers. These clinical trials established the safety and efficacy of
volociximab as single-agent or in combination [39]. All these
preliminary data demonstrate the efficacy of volociximab but
randomized trials and future studies are required to validate the
efficacy.
Intetumumab: Intetumumab (CNTO 95) is a fully human IgG1
mAb which do not cross react with mouse integrins but have limited
cross reactivity with rat integrins [40]. It is generated by immunizing
mice transgenic for part of the human immunoglobulin receptors. It
recognizes multiple αv integrins with broad specificity with a
dissociation constant of Kd 1-24 nmol [41]. Studies conducted showed
that CNTO 95 bound to purified human αvβ3 and αvβ5 integrins with
high specificity and as a promising agent to inhibit integrin mediated
tumor growth and angiogenesis [42]. It inhibits angiogenesis in
tumors by ligating with the integrin receptors on the tumor cells and
thereby blocking or reducing the signalling between the tumor cells
and ECM [43]. The in vivo preclinical studies in nude mice and nude
rats demonstrated that CNTO 95 has potent anti-tumor and anti-
angiogenic properties where intetumumab dose dependently inhibited
the adhesion of HUVECs and human melanoma cells to all αvβ3 and
αvβ5 ligands, indicating the function blockade of αvβ3 and αvβ5
integrins. The in vitro sprouting and inhibitory studies demonstrated
CNTO 95 as an inhibitor of angiogenesis because the proliferation of
bFGF simulated endothelial cells was inhibited by intetumumab in
dose dependent manner compared to unstimulated cells [40]. Another
preclinical study in cynomolgusmacque evaluated the safety of CNTO
95. The results postulated that terminal elimination half-life was
increased with dose and reduced clearance of mAb at 10 mg/kg and 50
mg/kg doses. The serum concentration time profile exhibited a short,
rapid distribution phase. The in vitro and in vivo immunolocalization
studies showed that CNTO 95 bound strongly to human and mouse
tissues. This preclinical data suggested that intetumumab is safe for
long term administration [44].
The supportive data in preclinical evaluations of intetumumab
exhibited the anti tumor and anti angiogenic inhibitory effects of the
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antibody. In the Phase I study of CNTO 95 the biological activities like
cell motility, cell signalling, tumor growth, tumor metastasis and
angiogenesis were determined by using breast carcinoma cells. In four
human breast cancer cells (MCF-7, MDA-MB-231, MDA-MB-468,
and MX-1) with estrogen positive and negative receptor showed the
reduction in cell viability by CNTO 95 in a dose dependent manner. It
also specifically inhibits the integrin αv-vitronectin receptor
suggesting potential effects of the mAb on cell motility and adhesion.
It inhibits this interaction by promoting tyrosine dephosphorylation of
FAK and paxillin. The MDA-MB-231 cells in SCID mice treated with
CNTO 95 resulted in significant inhibition of metastasis by providing
additional anti-cancer benefit [41]. An open label, single centre, first-
in-human, multiple administration, dose escalating (0.1, 0.3, 1.0, 3.0,
10.0 mg/kg) study in 24 patients evaluated the safety and
pharmacokinetics of CNTO 95. Over all the therapy was well tolerated
with only observation of dose related increase adverse events. The low
doses (≤3.0 mg/kg) cleared more rapidly from serum where as higher
dose (10 mg/kg) cleared more slowly indicating saturation of tissue
binding at 10.0 mg/kg. This pharmacokinetics studies indicate the
increase of drug exposure in greater than proportional manner over
the range evaluated. When pre-treated and post-treated tumor cells
with CNTO 95 were observed, the levels of Bcl-2, a proto-oncogene
which inhibits apoptosis was distinctly present in pre-treated tumor
cells. The immune-histochemical analysis indicate that CNTO 95 was
able to penetrate in to the tumor and bind to the target integrin αv
[45]. But this study did not provide any information regarding the
maximum tolerated dose (MTD) in pharmacodynamics studies.
Another multicentre, open-label Phase-I study conducted with higher
dose (20 mg/kg) of CNTO 95 than previous Phase-I (10 mg/kg) in 19
patients observed no dose limiting toxicity, no complete or partial
responses and adverse effects like head ache, vomiting, nausea, fatigue
were similar to that of previous study. Four patients experienced
disease progression, changes in mental status and two metastatic
melanoma patients had a stable disease response. The
pharmacodynamics assessments suggested down regulation of
integrin. AUC and Cmax increased proportionally every 3 weeks and
terminal t ½ was slightly longer for the 20 mg/kg dose than that of 10
mg/kg dose. These safety evaluation studies suggested the CNTO 95
maximum tolerated dose MTD of 10 mg/kg dose levels for future
studies [42]. The safety and efficacy of intetumumab as a single agent
or in combination with other agents by using radiation therapy was
established. The pharmacokinetics results in a multicentre,
randomized, Phase-II in stage-IV melanoma patients in combination
with dacarbazine were nonlinear with greater than dose- proportional
at 10 mg/kg serum concentrations. The therapy with intetumumab
and dacarbizine was well tolerated with association of very low grade
adverse effects in patients receiving intetumumab and patients treated
with dacarbazine experienced hematologic toxicity [46]. The in vitro
inhibitory studies in colon cancer cell lines (HCT 116 which express
αvβ5 and RKO cells which express α6β1, α2β1, α6β4) conferred that
combination regimen of CNTO 95 and dasctinib were greater than
drug alone. This dual inhibition reduced paxillin activation and inhibit
cell migration in HCT 116 cells but not in RKO cells in low
concentrations [47].
The intetumumab and radiation combination therapy in human
tumor xenografts and rats established, intetumumab as a potent and
effective agent for cancer therapy along with radiation. The human
xenograft model in nude rats established with human head, neck and
non-small cell lung cancer cell lines established the effectiveness of
intetumumab in combination with radiation therapy. A limited
antitumor activity was observed with a significant reduction of
VEGFR and integrin αv expression along with the density reduction of
micro vessels [48]. It also inhibited spontaneous lung metastasis of A
549 tumors. When radiation therapy is combined with intetumumab
the perfusion rate and blood volume in tumours were enhanced
significantly which were totally different as a single agents of treatment
[49]. These results encouraged the potent efficacy of intetumumab
along with fractionated radiation therapy and were consistent with the
Phase-I.
Studies from uterine serous papillary carcinoma (USPC), colorectal
adeno carcinoma, breast cancer demonstrated the anti-metastatic and
prognostic effect of intetumumab. The cell adhesion of uterine serous
papillary carcinoma (USPC) cell lines that express αv integrins to ECM
proteins were significantly inhibited at low doses of intetumumab. The
in vitro and in vivo studies employing 8.0 µm pore poly carbonate
membrane demonstrated the ability of intetumumab to inhibit the
migration of uterine serous papillary carcinoma cells [43]. In a
hematogenous metastasis study the rats treated with intetumumab did
not develop any brain lesions compared to contrast result of control
rats. Intetumumab significantly improved the survival and incidence
of multiple brain metastases in MRI was also reduced. It also reduced
the human 231 BR-HER2 cells adhesion to the cultured plates with
97-100% viability [50]. These results emphasized the prophylactic
effect and the anti-metastatic effect of intetumumab in nude rats. A
recent study in non-small cell lung cancer (NSCLC) assessed the
potential growth inhibition mechanism by using intetumumab. In the
cells deleted with SMARCA 4 gene, ZEB 1 gene expression was up
regulated whereas E-cadherin expression was down regulated. These
results to gain the information regarding the inhibition mechanism
and suggest ZEB I acquires SMARC 4 independent mechanism to
repress E-cadherin expression. The results also showed strong
enrichment in several chromosomal locations in which the down
regulated genes were highly enriched on chromosome 19p while the
up regulated genes were enriched on chromosome 4q in resistant cells
[51]. This information is necessary to support further clinical
evaluation of intetumumab to evaluate the antitumor and anti
angiogenic effects.
EMD 525797 (DI17E6): EMD 525797 (DI17E6) is a novel de-
immunized monoclonal immunoglobulin G2 antibody that is
developed specifically to direct against the human αv integrins. It
prevent the cell adhesion and motility of the tumor cells by binding to
the human αv integrins and inhibits the ligand binding to all αv
heterodimers thereby antagonizing their interactions. The Phase-I
studies evaluated the safety, efficacy, tolerability, anti-tumor activity
and pharmacokinetics of the DI17E6. In a multicentre, open-label,
dose escalating (250 mg, 500 mg, 1000 mg, 1500 mg) study enrolled
with 26 patients of metastatic CRPC showed a dose-dependent and
non-linearity pharmacokinetics profile of EMD 525797. The terminal
elimination half-life of low dose (250 mg) observed approximately
four fold divergence when compared to high dose level (1500 mg). No
DLTs and dose dependent relationship in TEAEs were observed. But
there was significant decrease in primary tumor only in one patient
and over all the treatment with EMD 525797 was well tolerated and it
appeared to be safe in metastatic CRPC patients [52]. In another
Phase-I, first-in-human study with 54 subjects studied observed the
EMD 525797 elimination from serum with t ½ of 13 fold difference to
1500 mg dose group. The results demonstrated that the
pharmacokinetics of EMD 525797 was dose-dependent with dose
proportion increase of Cmax values and treatment was well tolerated
with ascending doses of EMD 525797 (35 mg to 1500 mg) [53]. A
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Phase-II randomized, double-blind placebo controlled in mCRPC
patients was ongoing with 750 mg and 1500 mg of EMD 525797 [52].
Over all these results suggest EMD 525797 as a potent single agent
inhibitor but further evaluation of predictive markers and controlled
randomized trials are necessary to evaluate the efficacy of the EMD
52579.
GIPG0187: GIPG0187 is a non-peptide RGD antagonist for all six
integrin receptors. It displays a unique anti-integrin, anti-tumor, anti
angiogenic, anti-osteoporotic and anti-resorptive profile [54]. In
human prostate cancer PC-3M-Pro4/luc+ cells treated with
GIPG0187, reduced tumor growth and bone metastases were
observed. It diminished the aldehyde dehydrogenase and increased the
E-Cadherin/vimentin ratio in the in vivo study performed in the
prostate cancer cells. In the in vitro study it significantly prevented the
ORX-induced bone loss and reduced the number of osteoclasts. These
in vitro and in vivo results suggest it as a potent inhibitor of
angiogenesis [15]. The exposure of the GIPG0187 to GL-261 and
SMA-560 mouse glioma cells resulted in reduced viability and cell
death at very low concentrations (1 nM). Also the impaired TGF-β
signalling was observed when pSmad2 levels were reduced in GL-261
and SMA-560 mouse glioma cells cultured on the collagen-1 coated
cell plates [55]. This agent progressed to clinical trials in advanced
cancers with the supportive results from Phase-I and further
evaluation is much more important for cancer therapy.
MK0429: MK0429 is a small, active, potent, non-peptide αvβ3
integrin inhibitor [23,56]. It functions to have potent inhibition
activity for osteoclast formation and osteoclastic bone resorption. In
multicentre, randomized Phase-I double-blind trail enrolled with 21
HRPC and bone metastatic patients, rapid absorption of mk-0429 at
lower dose was evident. The treatment was well tolerated with no
DLTs and adverse effects and assumed to be safe [57]. Even though the
positive results for safety and tolerability were observed for this orally
bioavailable compound it is not being developed.
PSK1404: PSK1404 is a non-peptide antagonist for αvβ3 integrin
[58]. It inhibits osteoclast bone resorption and exhibits antitumor
effect in ovarian and breast cancer cells. In in vitro and in vivo studies
it significantly blocked the tumor cell invasion and inhibited bone
marrow colonization in αvβ3 integrin expressing cancer cells. It also
exhibits multiple inhibitory effects on endothelial cells, cancer cells
and osteoclasts [16]. But very limited pre-clinical study is done further
evaluation of PSK 1404 is very vital to understand the αvβ3 integrin
inhibitory mechanism in bone metastases therapy.
IH1062: IH1062 (3,5-dichlorophennylbiguanide) is an effective αvβ3
integrin inhibitor derived form 3, 4-dichlorophenylbiguanide. It
specifically inhibits the binding of αvβ3 integrin to its vitronectin
(ligand to αvβ3 integrin) and leads to cellular apoptosis. In M21
(human melanoma cell line) it induced anoikis, lead to decrease of
Bcl-2/Bax ratio and survivin proteins, dephosphorylate Tyr925 in the
carboxyl region of FAK. It also inhibited the pulmonary metastases in
established melanoma pulmonary metastasis mouse model in dose
dependent manner [59]. These in vitro and in vivo results established
for IH1062 in human melanoma cells is promising development to
treat and prevent tumor metastasis.
DisBa-01: DisBa-01 is a novel monomeric P-II SVMP-derived RGD
disintegrin. It is derived from venom gland RNAs of
Bothropsalternatus by recombinant DNA techniques. It interacts in a
stable and specific manner with purified αvβ3 integrin, induced by
bFGF in endothelial cells [60]. DisBa-01 inhibits angiogenesis in a dose
dependent manner and by reducing the expression of VEGF and its
receptors significantly. In HMEC cells at 10 nM and 100 nM
concentrations of DisBa-01 showed the down regulated VEGFR1 and
VEGFR2. In fibroblasts it contributed to reduce migration ability by
inhibiting the MMP-2 activity. It also impaired the proliferation by
αvβ3 and inhibits the adhesion of B16F10 and HMEC-1 to vitronectin.
These in vitro reports demonstrate the anti-adhesive properties of
DisBa-01. The ex vivo and in vivo studies demonstrate the anti-
metastatic and protective effect of disintegrin [61]. All these results
describe the essentiality to understand the molecular mechanism
underlying that target integrin-mediated processes using novel anti-
metastatic therapies.
S137 and S247: These are non-peptidic and β-amino acid
compounds. The potency of the S137 is slightly lower than S247. Both
these compounds inhibit the cell growth, motility, adhesion and
enhance the apoptosis of tumor cells in dose dependent manner. In
vitro results suggest that they actively inhibit ligand binding to αv
integrin and induce apoptosis in HUVEC cells [62,63]. The
continuous regime of S247 in an animal model significantly reduced
the development of liver metastases with better survival.
17E6: 17E6 is a function blocking, non-RGD, allosteric inhibitor
which contacts exclusively the propeller domain of αv integrin. 17E6
antibody behaves as an extracellular ligand and promotes the
endocytosis of αvβ3 integrin by preferring integrin dependent-
receptor mediated pathway. It alters the distribution of αv integrins on
the cell surface and induces the relocalization of focal adhesion
proteins [64]. It possesses anti-tumor, anti-adhesive, anti-metastasis
activities and interacts specifically against the human and primate αvβ3
αvβ1 and αvβ5 integrins [65,66]. 17E6 significantly inhibited the
adhesion of vitronectin and fibrinogen, ligands of αv integrins to
cutaneous melanoma DX3 line [67]. A strong morphological change
was induced in adhered M21 melanoma cells and blockade of tumor
growth was observed in nude mice suggesting the anti-tumor activity
of the compound [68]. In signalling cascade events 17E6 plays a vital
role by promoting FAK phosphorylation, partially interrupting
apoptotic signalling pathway that is activated by β-amyloid, activating
FAK/paxillin/p130 CAS signalling pathway, inhibiting the tumor
suppresser p53 protein expression, activating cell survival via
PI3K/Akt signaling [69]. In the performed in vivo study significantly
hindered the tumor growth in the positive αvβ3 xenografts that express
the melanoma cells [70]. Study performed using infected macrophages
reported a reduced HIV-1 Bal proviral DNA and also inhibited the
HIV infection at an early stage of the viral cycle suggesting the
interference of 17E6 for HIV replication in macrophages [71].
Currently this monoclonal antibody was in clinical trials for treating
cancer.
ATN-161: ATN-161 is a five amino acid acetylated, amidated
PHSCN peptide derived from the synergy region of human fibronectin
PHSRN sequence [72]. The Arginine amino acid in the original
sequence is replaced with cysteine residue. ATN-161 induces
neovascularization in matrigel plug assays performed in nude mice
and observed a dose dependent regulation of α5β1 integrin in human
microvascular endothelial cells [73]. These down regulation of α5β1
integrin resulted in apoptosis through the suppression of the Akt
activity [74]. PHSCN peptide sequence reduced the tumor growth in
rats to much more extent than rats treated with HSPNC which was
inactive (because tumor growth in rats treated with HSPNC increased
rapidly in both treated and untreated) suggesting the anti-tumorigenic
activity of the peptide [75]. In the murine colon cancer model it
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decreases the formation of liver metastases with enhanced survival,
proposing the anti-metastatic activity [18]. It is also the first PHSRN
synergy potent inhibitor sequence with anti-tumorigenic and anti-
metastatic to be evaluated in clinical trials where it prevented
progression of metastatic disease and recurrence for prolonged periods
[76]. In preclinical and Phase-I trials using lewis lung carcinoma and
HT 29 colon carcinoma model a U-shaped dose response was
observed for ATN-161 peptide with rapid clearance from serum [77].
The therapy with ATN-161 administration in combination with
tetrathiomolybdate and also with 5-flurouracil also suggested the
ATN-161 as more anti-tumorigenic agent [18,78]. Few other
analogues of ATN-161 like ATN-453, PHSCN-polylysine dendrimer
(Ac-PHSCNGGK-MAP), PhScN (where Histidine and Cysteine were
replaced with D-isomers), PHSC(S-OAc)N, PHSC(S-Me)N, PHSC(S-
acm)N reported to be more potent in metastatic human prostate
cancer cells [20]. The Phase-II clinical trials of this agent are
proceeding to be extremely changeling because no maximum tolerated
dose was achieved in former trials.
Resveratol: Resveratol (3, 4’, 5-trihydroxy-trans-stilbene) is natural
polyphenolic antioxidant found in plants and fruits (mostly grapes) in
Cis and trans stereoisomer forms, the trans isomer being significantly
more potent than Cis isoform. It regulates the expression of various
genes encoding to integrins that are involved in cellular process like
apoptosis, metastasis, adhesion and angiogenesis [79,80]. The in vitro
and in vivo studies showed the inhibitory ability of the Resveratol in
chick embryo and murine melanoma B16 by inhibiting the adhesion
by down regulation of cellular α5β1 integrins [81]. A recent study
reported that in the treatment with Res inhibited the adhesion of
ovarian cancer cell to HPMCs, dose dependently [82]. The receptor
sites on α5β1 integrin for Res induces apoptosis that is p53-dependent
via ERK 1/2 mediated pSer15 and also requires pool of inducible
cyclogenase-2 [83]. However more clinical studies regarding the
mechanism of action and how resveratol induces apoptosis are yet to
be examined.
Conclusion
In recent years, great progress has been made towards integrin
antagonists that target cancer. Their effectiveness in blocking tumour
progression has been demonstrated in preclinical as well as clinical
studies. At present there are multiple ongoing clinical trials on integrin
antagonists agents and few other novel compounds like JSM6427 [84],
β-lactam derivatives [6] and a Tenascin (TN)-C derived TNIIIA2
peptide [85] showed promising biological activity to target integrins
but in depth investigations are necessary for these compounds in the
malignancies that express high levels of integrins.
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